ライフサイエンスコーパス: memorial

1 ion, I did not really want to compose my own memorial.

2 PCA-specific anxiety was measured with the Memorial Anxiety Scale for Prostate Cancer (MAX-PC).

3 istorical perspective the 1985 G.H.A. Clowes Memorial Award Lecture delivered by Dr. Judah Folkman.

4 Levin et al., conducted at the Roswell Park Memorial Cancer Institute in the 1940s.

5 In 2016, Tata Memorial Center in Mumbai, India, reached its platinum j

6 cted patients presenting to the S. P. Botkin Memorial Clinical Hospital of Infectious Diseases, St. P

7 h a lower risk (OR = 0.72; p = 0.015), while Memorial Day was associated with a higher risk of a posi

8 ed Edmonton Symptom Assessment Scale (ESAS), Memorial Delirium Assessment Scale (MDAS), Nursing Delir

9 week using the Delirium Rating Scale and the Memorial Delirium Assessment Scale from 7 days before tr

10 week using the Delirium Rating Scale and the Memorial Delirium Assessment Scale.

11 Memorials for victims might complicate such attempts and

12 elgene Corporation and Richard Spencer Lewis Memorial Foundation and Cancer Center Support Grant.

13 tutes of Health, Mayo Clinic, and Kathy Shih Memorial Foundation.

14 ation of Queensland, Kasey-Anne Oklobdzijato Memorial Fund, the Australasian Leukaemia and Lymphoma G

15 COVID-19) from sites across the Northwestern Memorial Health Care System from February 2020 to April

16 t patients hospitalized with COVID-19 in the Memorial Healthcare System (Hollywood, Florida) between

17 ical trial was performed at the Northwestern Memorial HealthCare system in Chicago, Illinois.

18 dy was performed on 218 CHD patients seen at Memorial Hermann Hospital during the influenza season of

19 pital in Salt Lake City, Utah and Children's Memorial Hermann Hospital in Houston, Texas.

20 MRSA and 22,393 non-MRSA patient events from Memorial Hermann Hospital System, Houston, Texas are use

21 trospectively retrieved from SOT database in Memorial Hermann Hospital Texas Medical Center.

22 and tertiary pediatric hospital (Children's Memorial Hermann Hospital).

23 Memorial Hermann Hospital, one of only two level I traum

24 rom the Red Duke Trauma Institute within the Memorial Hermann Hospital-Texas Medical Center and Ben T

25 tory MAC isolates from 131 patients at Grady Memorial Hospital (Atlanta) and 13 MAC isolates from the

26 h post-trauma (range 0.5-12 h)) in the Grady Memorial Hospital (Atlanta) and Jackson Memorial Hospita

27 ty Winship Cancer Institute, including Grady Memorial Hospital (Atlanta, Georgia), from August 7, 201

28 niversity Hospital in Sweden, and Chang Gung Memorial Hospital (CGMH) in Taiwan, obtaining C-indices

29 secutively enrolled patients at Northwestern Memorial Hospital (Chicago, IL, USA) who were aged young

30 (1) the Emergency Departments (ED) at Grady Memorial Hospital (GMH) in Atlanta, GA, (2) from multipl

31 tients with <200 CD4 cells/mm3 seen at Grady Memorial Hospital (GMH), 11 (17%) of 66 with a history o

32 o February 28, 2018, at Kaohsiung Chang Gung Memorial Hospital (Kaohsiung, Taiwan).

33 rady Memorial Hospital (Atlanta) and Jackson Memorial Hospital (Miami) emergency departments.

34 ed for all patients presenting to Chang Gung Memorial Hospital (Taipei, Taiwan) and Michigan Medicine

35 Sinai Medical Center [MSMC] and Northwestern Memorial Hospital [NMH]) from January 1, 2013, to Novemb

36 plication cohort from patients visiting Tata Memorial Hospital between Aug 4, 2015, and May 17, 2016,

37 patients admitted at the King Chulalongkorn Memorial Hospital during May 1, 2011 to Dec 31, 2013.

38 malignant GIST were admitted and treated at Memorial Hospital during the past 16 years.

39 analyzed patients at the Keelung Chung Gung Memorial Hospital during the period from March 2005 to J

40 er visiting all departments or units of Tata Memorial Hospital during the same time period and freque

41 ss-sectional study carried out in Minilik II Memorial Hospital eye clinic, Addis Ababa, Ethiopia from

42 metastases from sarcoma who were admitted to Memorial Hospital from 1982 to 2000, and 56 of them unde

43 r corneal edema seen at Kaohsiung Chang Gung Memorial Hospital from January 1, 2007 to January 31, 20

44 derwent reduced intensity HSCT at Children's Memorial Hospital from January, 2000, to February, 2004.

45 tion-based study was conducted at Chang Gung Memorial Hospital from March 1, 2009, to March 1, 2020.

46 s who enrolled at the Diabetes Unit of Grady Memorial Hospital in Atlanta, Georgia, from April 16, 19

47 ents entered by 1961 care providers at Grady Memorial Hospital in Atlanta, Georgia, to 15,534 Canonic

48 hly traumatized civilian population at Grady Memorial Hospital in Atlanta, Georgia.

49 in the emergency department (ED) at Parkland Memorial Hospital in Dallas, TX.

50 cataract surgery at the Kaohsiung Chang Gung Memorial Hospital in year 2008 and year 2018.

51 gram developed at Emory University and Grady Memorial Hospital is offered as a model for educating su

52 Wishard Memorial Hospital is the county hospital affiliated with

53 for ROP between 1990 and 2019 at the Jackson Memorial Hospital neonatal intensive care unit.

54 lly indicated echocardiogram at Northwestern Memorial Hospital or Minneapolis Heart Institute between

55 ts (>=18 years old) admitted to Northwestern Memorial Hospital or Prentice Women's Hospital (both in

56 treated with platinum-based chemotherapy on Memorial Hospital protocols from 1975 to 1990 were analy

57 ugh March 31, 1987, using the Saint Margaret Memorial Hospital Rheumatoid Arthritis Registry, Pittsbu

58 gle-institution phase III trial conducted at Memorial Hospital served as the impetus for an intergrou

59 tential living donor at Kaohsiung Chang Gung Memorial Hospital were included.

60 ber 2020, patients treated at the Chang Gung Memorial Hospital with curative or postoperative IMRT fo

61 mory, Maccabi-Assuta, Karolinska, Chang Gung Memorial Hospital, and Barretos, respectively.

62 elapsing-remitting MS, attended Northwestern Memorial Hospital, and despite treatment with interferon

63 s, we conducted a prospective study at Grady Memorial Hospital, Atlanta, Ga.

64 t oral/maxillofacial surgery clinic at Grady Memorial Hospital, Atlanta, GA.

65 rcus Stroke and Neuroscience Center at Grady Memorial Hospital, Atlanta, Georgia.

66 AC clinical isolates from King Chulalongkorn Memorial Hospital, Bangkok, Thailand were carried out.

67 ified by CT or MRI at the King Chulalongkorn Memorial Hospital, Bangkok, Thailand were prospectively

68 outpatient eye clinic of King Chulalongkorn Memorial Hospital, Bangkok, Thailand, and from the eye c

69 HCC treated with TACE at King Chulalongkorn Memorial Hospital, Bangkok, Thailand, between January 20

70 ncer Institute of Emory University and Grady Memorial Hospital, both in Atlanta, Georgia.

71 urban academic medical center (Northwestern Memorial Hospital, Chicago, Illinois).

72 BSC) between February to May to Northwestern Memorial Hospital, Chicago, was compared between the pre

73 ase 1 was a single-centre study done in Tata Memorial Hospital, India, in patients aged 18 years or o

74 lbladder cancer diagnosed or treated at Tata Memorial Hospital, Mumbai, India, and enrolled in the st

75 sed case-control study conducted at the Tata Memorial Hospital, Mumbai.

76 h strains were multi-resistant in Chang Gung Memorial Hospital, one of the biggest referral centers i

77 al Research Foundation Singapore, Chang Gung Memorial Hospital, Recruitment Program for Young Profess

78 Movement Disorders Clinic in the Chang Gung Memorial Hospital, Taiwan.

79 mized controlled trial at King Chulalongkorn Memorial Hospital, Thailand, 204 adults with presumed pu

80 ents who were admitted at King Chulalongkorn Memorial Hospital.

81 ncer Institute of Emory University and Grady Memorial Hospital.

82 were recruited from Scripps Health/ Scripps Memorial Hospital/ Scripps Mericos Eye Institute between

83 Cone Memorial Hospital; this case became the landmark decisio

84 se is the Stolpersteine ("stumbling stones") memorial in Berlin, Germany.

85 c effects." METHODS: CA-MHB and Roswell Park Memorial Institute (RPMI) 1640 medium (used for growing

86 ively) in an organ culture with Roswell Park Memorial Institute 1640 (30% serum) for 0, 4, 7, 10, and

87 e's medium/Ham's F12 (DMEM) and Roswell Park Memorial Institute 1640 medium (RPMI) supported the larg

88 versus 1346+/-84 um(3) in RPMI (Roswell Park Memorial Institute medium) control group (P=0.003), whil

89 nitive capacity for perceptual decisions and memorial judgments and used resting-state functional con

90 in metacognitive ability for perceptual and memorial judgments.

91 ts of my presentation at the Thomas W. Smith Memorial Lecture at American Heart Association Scientifi

92 s were studied in the Neonatal Unit, Simpson Memorial Maternity Pavilion, Edinburgh, UK.

93 TING, AND PARTICIPANTS: A multicenter (UMass Memorial Medical Center and Louisiana State University H

94 ave birth at the University of Miami/Jackson Memorial Medical Center from 1990 through 2002.

95 s old, residing in Conemaugh Health System's Memorial Medical Center's service area.

96 retrospective study was conducted at Jackson Memorial-Miami Transplant Institute.

97 oring the beams of the National September 11 Memorial & Museum's "Tribute in Light" in New York, quan

98 dary outcomes were immediate change in mood (Memorial Pain Assessment Card) and 60-second heart and r

99 Primary outcomes were immediate (Memorial Pain Assessment Card, 0- to 10-point scale) and

100 can be taken to indicate that perceptual and memorial processes are not functionally independent, but

101 procedures to show that rats formed distinct memorial representations of 2 (peanut oil and sucrose pe

102 Among 525 individuals with Covid-19 from Memorial Sloan Kettering (MSK) and the Korean Clonal Hem

103 abels assigned by teacher models and sent to Memorial Sloan Kettering (MSK) for evaluation.

104 t from the Cancer Genome Atlas (TCGA), and a Memorial Sloan Kettering (MSK) observational immunothera

105 Prospective databases at Memorial Sloan Kettering (MSK), Massachusetts General Ho

106 Here we develop MSK-ACCESS (Memorial Sloan Kettering - Analysis of Circulating cfDNA

107 es of symptomatic COVID-19 were diagnosed at Memorial Sloan Kettering Cancer Center (from a total of

108 onal diploid-subclonal (KEAP1 CD-SC)] in the Memorial Sloan Kettering Cancer Center (MSK) MetTropism

109 trecht (UMC)/Princess Maxima Center (PMC) or Memorial Sloan Kettering Cancer Center (MSK) were includ

110 s of consecutive NLPHL patients diagnosed at Memorial Sloan Kettering Cancer Center (MSK), with a foc

111 om women undergoing breast reconstruction at Memorial Sloan Kettering Cancer Center (MSKCC) between J

112 nd 17 had at least one unfavorable factor by Memorial Sloan Kettering Cancer Center (MSKCC) criteria.

113 f Surgical Oncology (SSO) guidelines and the Memorial Sloan Kettering Cancer Center (MSKCC) online no

114 etrospective review of 125 adult patients at Memorial Sloan Kettering Cancer Center (MSKCC) who recei

115 in the Dana-Farber Cancer Institute (DFCI), Memorial Sloan Kettering Cancer Center (MSKCC), and in t

116 e-body/-blood clearance (WB/BC) dosimetry at Memorial Sloan Kettering Cancer Center (MSKCC, n = 121).

117 e-body/-blood clearance (WB/BC) dosimetry at Memorial Sloan Kettering Cancer Center (MSKCC, n = 121).

118 tion of primary, non-metastatic GISTs at the Memorial Sloan Kettering Cancer Center (MSKCC; New York,

119 the Molecular Imaging and Therapy Service at Memorial Sloan Kettering Cancer Center (New York, NY) an

120 the Molecular Imaging and Therapy Service at Memorial Sloan Kettering Cancer Center (New York, NY) an

121 tion of colorectal liver metastases from the Memorial Sloan Kettering Cancer Center (New York, NY, US

122 ed patients aged 18 years and older from the Memorial Sloan Kettering Cancer Center (New York, NY, US

123 eted sequencing data from seven cohorts (the Memorial Sloan Kettering Cancer Center [MSKCC] cohort [t

124 de, and Necrosis [SSIGN]; Leibovich; Kattan; Memorial Sloan Kettering Cancer Center [MSKCC]; Yayciogl

125 as conducted from March 2012 to July 2023 at Memorial Sloan Kettering Cancer Center and included 55 p

126 sions from the dermatologic surgery units at Memorial Sloan Kettering Cancer Center and Oregon Health

127 py Service in the Department of Radiology at Memorial Sloan Kettering Cancer Center and professor of

128 ly developed slightly different schemes (the Memorial Sloan Kettering Cancer Center and Sydney grade)

129 underwent ALND or SLNB from 1999 to 2020 at Memorial Sloan Kettering Cancer Center and the Mayo Clin

130 s eligible for studies of targeted agents at Memorial Sloan Kettering Cancer Center are offered tumor

131 l of 4915 liver resections were performed at Memorial Sloan Kettering Cancer Center between 1992 and

132 g data of 327 NET patients were collected at Memorial Sloan Kettering Cancer Center between December

133 ients referred to the Dermatology Service at Memorial Sloan Kettering Cancer Center between January 1

134 e indices in two independent cohorts of 154 (Memorial Sloan Kettering Cancer Center cohort [MSKCC] co

135 wn to attendees of a dermoscopy course (2014 Memorial Sloan Kettering Cancer Center dermoscopy course

136 analyzed data from institutional records at Memorial Sloan Kettering Cancer Center from 1985 to 2015

137 h metastatic breast cancer were performed at Memorial Sloan Kettering Cancer Center from 2008 to 2019

138 lt patients who received methylnaltrexone at Memorial Sloan Kettering Cancer Center from 2009-2016.

139 All patients with PS II NSGCT seen at Memorial Sloan Kettering Cancer Center from March 1989 t

140 ved intravitreous injections of melphalan at Memorial Sloan Kettering Cancer Center from September 12

141 fied National Institutes of Health criteria, Memorial Sloan Kettering Cancer Center GIST nomogram, an

142 Since 1962, Memorial Sloan Kettering Cancer Center has used an indiv

143 censed the bank of third-party EBV-CTLs from Memorial Sloan Kettering Cancer Center in June 2015.

144 PC and patients with PRC who were treated at Memorial Sloan Kettering Cancer Center in New York betwe

145 or without urine microscopy was performed at Memorial Sloan Kettering Cancer Center in New York City,

146 Clinical and correlative pilot study at the Memorial Sloan Kettering Cancer Center in New York, New

147 Patients of Memorial Sloan Kettering Cancer Center in New York, New

148 Ross Levine is a physician-scientist at Memorial Sloan Kettering Cancer Center in New York, wher

149 gle-centre, single-arm, phase 2 trial at the Memorial Sloan Kettering Cancer Center in the USA.

150 ologic assessments at Indiana University and Memorial Sloan Kettering Cancer Center included 100 part

151 Drug Administration-cleared multigene panel [Memorial Sloan Kettering Cancer Center Integrated Mutati

152 The overall accuracy of the Memorial Sloan Kettering Cancer Center nomogram was high

153 compared with the predictions of the updated Memorial Sloan Kettering Cancer Center nomogram.

154 ter screening 1,488 patients or relatives at Memorial Sloan Kettering Cancer Center or three related

155 Stratification factors were Memorial Sloan Kettering Cancer Center prognostic group

156 ication factors were geographical region and Memorial Sloan Kettering Cancer Center prognostic groups

157 d were stratified by geographical region and Memorial Sloan Kettering Cancer Center prognostic groups

158 Memorial Sloan Kettering Cancer Center risk category was

159 Randomisation was stratified by Memorial Sloan Kettering Cancer Center risk group and pa

160 Stratification factors were Memorial Sloan Kettering Cancer Center risk group and th

161 o HR for PD-L1 1%, 1.36; 95% CI, 1.10-1.68), Memorial Sloan Kettering Cancer Center risk score (PFS:

162 Geriatricians at Memorial Sloan Kettering Cancer Center risk-stratify sur

163 negative (not-BCC) samples were collected at Memorial Sloan Kettering Cancer Center to create three t

164 tumour genomic data from 24,950 patients at Memorial Sloan Kettering Cancer Center to generate a cli

165 nt chemotherapy for advanced solid tumors at Memorial Sloan Kettering Cancer Center to report 12 comm

166 We reviewed prospective trials at Memorial Sloan Kettering Cancer Center using (18)F-FES P

167 ergoing colorectal and gynecology surgery at Memorial Sloan Kettering Cancer Center who were schedule

168 e prospectively collected on patients at the Memorial Sloan Kettering Cancer Center with (177)Lu-DOTA

169 een November 2015 and June 2018, patients at Memorial Sloan Kettering Cancer Center with primary or r

170 t the Josie Robertson Surgery Center (JRSC), Memorial Sloan Kettering Cancer Center's ambulatory surg

171 sylvania Hospital Abramson Cancer Center and Memorial Sloan Kettering Cancer Center).

172 From January 2014 until May 2016 at Memorial Sloan Kettering Cancer Center, 10336 patients c

173 ts: For this cross-sectional cohort study at Memorial Sloan Kettering Cancer Center, 265 men with pro

174 , open-label clinical trial conducted at the Memorial Sloan Kettering Cancer Center, 60 patients 18 y

175 at the Dana-Farber Cancer Institute (DFCI), Memorial Sloan Kettering Cancer Center, MD Anderson Canc

176 CD19-directed CAR T cells (Stanford, N = 51; Memorial Sloan Kettering Cancer Center, N = 69).

177 ies reports a single-institution experience (Memorial Sloan Kettering Cancer Center, New York, New Yo

178 pproved by the Institutional Review Board at Memorial Sloan Kettering Cancer Center, the FDA, and the

179 c antigen receptor T cell (CAR T) therapy at Memorial Sloan Kettering Cancer Center, we aimed to iden

180 At Memorial Sloan Kettering Cancer Center, we have focused

181 retrospective cohort study was performed at Memorial Sloan Kettering Cancer Center, with patients tr

182 spital/Dana-Farber/Harvard Cancer Center and Memorial Sloan Kettering Cancer Center.

183 HLA-A, HLA-B, and HLA-DRB1 was performed at Memorial Sloan Kettering Cancer Center.

184 d with first-line chemotherapy and/or ICB at Memorial Sloan Kettering Cancer Center.

185 reated between August 2010 and April 2022 at Memorial Sloan Kettering Cancer Center.

186 233 tests before surgeries or procedures at Memorial Sloan Kettering Cancer Center.

187 Institute P30 Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center.

188 m 1,628 patients across 17 cancer types from Memorial Sloan Kettering Cancer Center.

189 ill, followed by a postdoc with Alan Hall at Memorial Sloan Kettering Cancer Center.

190 31, 2017, at the Dermatology Service of the Memorial Sloan Kettering Cancer Center.

191 Cohorts were recruited from the Memorial Sloan Kettering Cancer Center; Melanoma Unit of

192 Bulk disease defined by Memorial Sloan Kettering criteria (> 7 cm in maximal tra

193 Grade 2 and 3 glioma cases from the Memorial Sloan Kettering dataset (n = 404) and Grade 3 g

194 eated with single-agent anti-PD-1 therapy at Memorial Sloan Kettering from 2009-2018 who had disconti

195 with various types of advanced tumours (the Memorial Sloan Kettering Integrated Mutation Profiling o

196 f patients with UrC-ADC from 2001 to 2019 at Memorial Sloan Kettering was performed.

197 uenced between January 2014 and July 2015 at Memorial Sloan Kettering were recruited.

198 uenced between January 2014 and July 2015 at Memorial Sloan Kettering were recruited.

199 Memorial Sloan Kettering's New York State-approved gene

200 age of 32 years: 50% men, 98% stage II, 86% Memorial Sloan Kettering-defined disease bulk, 27% tradi

201 Ten specimens were interrogated with Memorial Sloan Kettering-Integrated Mutation Profiling o

202 Genomic data were derived from the Memorial Sloan Kettering-Integrated Mutation Profiling o

203 In Memorial Sloan Kettering-Integrated Mutation Profiling o

204 treatment blood sequencing performed through Memorial Sloan Kettering-Integrated Mutation Profiling o

205 performed through an institutional platform (Memorial Sloan Kettering-Integrated Mutation Profiling o

206 nd peripheral blood DNA sequencing using the Memorial Sloan Kettering-Integrated Mutation Profiling o

207 dromes as identified by targeted sequencing (Memorial Sloan Kettering-Integrated Mutation Profiling o

208 ia Information Exchange; 5087 participants), Memorial Sloan Kettering-Metastatic Events and Tropisms

209 ist, with nivolumab in refractory sarcoma at Memorial Sloan Kettering/MD Anderson Cancer Centers (NCT

210 Lefkovsky Family Foundation; the Society of Memorial Sloan Kettering; the Byrne fund; and Cycle for

211 ent liver resection between 1995 and 2000 at Memorial Sloan- Kettering Cancer Center, we modeled the

212 Memorial Sloan-Kettering (MSK), Johns Hopkins (JH), and

213 y (n = 9), University of Pittsburgh (n = 8), Memorial Sloan-Kettering (n = 7), John Wayne Cancer Inst

214 id cancer and who were already enrolled in a Memorial Sloan-Kettering Cancer Center (131)I thyroid ca

215 hieved with that approach, as carried out at Memorial Sloan-Kettering Cancer Center (MSKCC) and as re

216 patients with no evidence of disease seen at Memorial Sloan-Kettering Cancer Center (MSKCC) between 1

217 All patients admitted to Memorial Sloan-Kettering Cancer Center (MSKCC) for curat

218 t diagnosis consecutively ascertained at the Memorial Sloan-Kettering Cancer Center (MSKCC) for incid

219 mSv for the reference population, the total Memorial Sloan-Kettering Cancer Center (MSKCC) study pat

220 inserted in adult and pediatric patients at Memorial Sloan-Kettering Cancer Center (MSKCC) were foll

221 eatment Referral Center protocol 9103 at the Memorial Sloan-Kettering Cancer Center (MSKCC) were revi

222 ) was developed from 127 patients treated at Memorial Sloan-Kettering Cancer Center (MSKCC), New York

223 itial endoscopic biopsies (EGDs) reviewed at Memorial Sloan-Kettering Cancer Center (MSKCC).

224 patients with newly diagnosed PCNSL seen at Memorial Sloan-Kettering Cancer Center (MSKCC; New York,

225 tients (n = 660) with breast cancer from the Memorial Sloan-Kettering Cancer Center (New York, NY) an

226 mogram was developed and is available on the Memorial Sloan-Kettering Cancer Center (New York, NY) We

227 static bladder cancer treated on protocol at Memorial Sloan-Kettering Cancer Center (New York, NY) wi

228 patients who were treated in this fashion at Memorial Sloan-Kettering Cancer Center (New York, NY).

229 ant prostate cancer in a validation set from Memorial Sloan-Kettering Cancer Center (New York, NY, US

230 resistant prostate cancer recruited from the Memorial Sloan-Kettering Cancer Center (New York, USA) w

231 Patients treated at the Memorial Sloan-Kettering Cancer Center between 1980 and

232 ndomized analysis of patients treated at the Memorial Sloan-Kettering Cancer Center between 1988 and

233 three-dimensional conformal radiotherapy at Memorial Sloan-Kettering Cancer Center between 1991 and

234 ients with metastatic uveal melanoma seen at Memorial Sloan-Kettering Cancer Center between 1994 and

235 radical prostatectomy for prostate cancer at Memorial Sloan-Kettering Cancer Center between December

236 s admitted to the special care unit (SCU) of Memorial Sloan-Kettering Cancer Center between January 1

237 nt stem-cell transplantation for lymphoma at Memorial Sloan-Kettering Cancer Center between January 2

238 ctive database for gastric adenocarcinoma at Memorial Sloan-Kettering Cancer Center between July 1985

239 senting with periampullary carcinomas to the Memorial Sloan-Kettering Cancer Center between October 1

240 ively reviewed all patients entered into the Memorial Sloan-Kettering Cancer Center clinical data bas

241 670 patients with advanced RCC treated in 24 Memorial Sloan-Kettering Cancer Center clinical trials b

242 By Memorial Sloan-Kettering Cancer Center criteria, 82% of

243 Examples from the Memorial Sloan-Kettering Cancer Center CST program are i

244 erformed of patients who had been treated at Memorial Sloan-Kettering Cancer Center for MCC between 1

245 tive SLN biopsy procedures were performed at Memorial Sloan-Kettering Cancer Center for unilateral in

246 ely maintained database for patients seen at Memorial Sloan-Kettering Cancer Center from 1996 to the

247 t of Surgery prospective gastric database at Memorial Sloan-Kettering Cancer Center from July 1985 to

248 tabase for adenocarcinoma of the pancreas at Memorial Sloan-Kettering Cancer Center identified 332 pa

249 ntify all patients who received cetuximab at Memorial Sloan-Kettering Cancer Center in a nonstudy set

250 athologic factors and the performance of the Memorial Sloan-Kettering Cancer Center nomogram for pred

251 ow risk for metastasis since the report from Memorial Sloan-Kettering Cancer Center of a 90% survival

252 ssigned, stratified by prior nephrectomy and Memorial Sloan-Kettering Cancer Center prognostic group,

253 dated computer system, and was stratified by Memorial Sloan-Kettering Cancer Center prognostic score

254 March 2002 to November 2006, 98 patients at Memorial Sloan-Kettering Cancer Center received inductio

255 Using the Memorial Sloan-Kettering Cancer Center sphincter functio

256 dy was to evaluate a published nomogram from Memorial Sloan-Kettering Cancer Center to predict for ri

257 advanced HCC treated over a 5-year period at Memorial Sloan-Kettering Cancer Center were identified f

258 sarcoma from July 1982 through July 1995 at Memorial Sloan-Kettering Cancer Center were the subject

259 d and entered into a prospective database at Memorial Sloan-Kettering Cancer Center with a diagnosis

260 ing nervous system'; Dr Richard Kolesnick's (Memorial Sloan-Kettering Cancer Center) talk has been fo

261 At Memorial Sloan-Kettering Cancer Center, a method for gen

262 2010, and January 1, 2013, was conducted at Memorial Sloan-Kettering Cancer Center, a tertiary refer

263 cations (Eastern Cooperative Oncology Group, Memorial Sloan-Kettering Cancer Center, and Heng criteri

264 At Memorial Sloan-Kettering Cancer Center, IHC incidence ha

265 lung and genitourinary cancer clinics in the Memorial Sloan-Kettering Cancer Center, New York, NY, US

266 known pulmonary process from 1996 to 1998 at Memorial Sloan-Kettering Cancer Center, were retrospecti

267 spective case control study was conducted at Memorial Sloan-Kettering Cancer Center.

268 ateral breast cancer underwent mastectomy at Memorial Sloan-Kettering Cancer Center.

269 metastatic samples from a clinical cohort at Memorial Sloan-Kettering Cancer Center.

270 prospectively on 3 consecutive protocols at Memorial Sloan-Kettering Cancer Center.

271 eatic adenocarcinoma nomogram established at Memorial Sloan-Kettering Cancer Center.

272 low-up endoscopic gastroduodenal biopsies at Memorial Sloan-Kettering Cancer Center.

273 ly analyzed by G-banding, ascertained at the Memorial Sloan-Kettering Cancer Center.

274 tion from December 1991 to September 2001 at Memorial Sloan-Kettering Cancer Center.

275 Anderson Cancer Center in collaboration with Memorial Sloan-Kettering Cancer Center.

276 93 to December 1997 with ICE chemotherapy at Memorial Sloan-Kettering Cancer Center.

277 tissue sarcoma were admitted and treated at Memorial Sloan-Kettering Cancer Center.

278 Cancer Institute and CycleforSurvival Fund, Memorial Sloan-Kettering Cancer Center.

279 alt Lake City, UT), in pediatric patients at Memorial Sloan-Kettering Cancer Center.

280 York City, New York, the predecessor of the Memorial Sloan-Kettering Center for the Treatment of Can

281 venty-three patients with OS were treated at Memorial-Sloan Kettering Cancer Center (MSKCC) on the T1

282 tric adenocarcinoma underwent laparoscopy at Memorial-Sloan Kettering Cancer Center from December 199

283 Review of prospectively collected data at Memorial-Sloan Kettering Cancer Center was conducted.

284 tion (HISF), and the New York Hideyo Noguchi Memorial Society (HNMS).

285 pirit during its traverses from the Columbia Memorial station to Bonneville crater were determined wi

286 windblown sediments are seen at the Columbia Memorial Station where the Spirit rover landed.

287 st are present in the soil near the Columbia Memorial Station.

288 age- and respondent-adapted versions of the Memorial Symptom Assessment Scale (MSAS), Pediatric Qual

289 Outcomes Study (MOS) questionnaire, and the Memorial Symptom Assessment Scale (MSAS)--as well as ori

290 h patient at baseline and serially using the Memorial Symptom Assessment Scale (MSAS)-Global Distress

291 respondent-adapted versions of the PediQUEST Memorial Symptom Assessment Scale (PQ-MSAS) at most once

292 I, -0.37 to 0.53 points]), symptom distress (Memorial Symptom Assessment Scale global distress index,

293 tem Short-Form Health Survey (SF-12) and the Memorial Symptom Assessment Scale patient-reported quest

294 significant improvements in total SF-12 and Memorial Symptom Assessment Scale scores, as well as in

295 utcomes of interest were all other symptoms (Memorial Symptom Assessment Scale) and quality of life (

296 re, 0- to 10-point scale), symptom distress (Memorial Symptom Assessment Scale, 0- to 4-point scale),

297 a modification of the Condensed Form of the Memorial Symptom Assessment Scale.

298 study, we examine whether exposure to local memorials that commemorate victims of atrocities reduces

299 Our study suggests that local memorials that make past atrocities visible have implica

300 (Melbourne, VIC, Australia) and the Jayanti Memorial Trust (Kathmandu, Nepal).